Research statistics

Cerebrolysin research: publications and trials

What has been published on Cerebrolysin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Cerebrolysin works or is safe. For what it is and what the studies found, see the Cerebrolysin profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

591

Since 1973

Publications in 2026 so far

18

Through November 15, 2026

Human clinical research

37.5%

214 of 570 classified

Registered clinical trials

40

ClinicalTrials.gov

Randomized controlled trials

68

Publications reporting an RCT in people

Systematic reviews and meta-analyses

25

Preclinical studies

43.3%

225 animal · 19 in vitro · 3 computational

Records that only mention it

50

Not counted above

Status in the library: Research only. Groups: Cognitive and neurological peptides. 21 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Cerebrolysin publications by year and evidence

1973, Other and not yet classified: 1 of 11974, Other and not yet classified: 1 of 11975, Human clinical research: 1 of 51975, Preclinical (animal, in vitro, computational): 2 of 51975, Other and not yet classified: 2 of 51976, Human clinical research: 2 of 31976, Preclinical (animal, in vitro, computational): 1 of 31977, Other and not yet classified: 1 of 11980, Preclinical (animal, in vitro, computational): 1 of 21980, Other and not yet classified: 1 of 21981, Preclinical (animal, in vitro, computational): 1 of 21981, Other and not yet classified: 1 of 21982, Other and not yet classified: 1 of 11983, Other and not yet classified: 1 of 11985, Preclinical (animal, in vitro, computational): 2 of 21989, Other and not yet classified: 1 of 11990, Human clinical research: 3 of 31991, Human clinical research: 2 of 41991, Preclinical (animal, in vitro, computational): 2 of 41992, Preclinical (animal, in vitro, computational): 2 of 21993, Preclinical (animal, in vitro, computational): 1 of 21993, Other and not yet classified: 1 of 21994, Human clinical research: 2 of 51994, Preclinical (animal, in vitro, computational): 2 of 51994, Other and not yet classified: 1 of 51995, Human clinical research: 2 of 51995, Preclinical (animal, in vitro, computational): 3 of 51996, Human clinical research: 1 of 141996, Preclinical (animal, in vitro, computational): 12 of 141996, Other and not yet classified: 1 of 141997, Human clinical research: 4 of 81997, Preclinical (animal, in vitro, computational): 3 of 81997, Other and not yet classified: 1 of 81998, Human clinical research: 5 of 191998, Preclinical (animal, in vitro, computational): 13 of 191998, Reviews and meta-analyses: 1 of 191999, Human clinical research: 2 of 131999, Preclinical (animal, in vitro, computational): 9 of 131999, Reviews and meta-analyses: 1 of 131999, Other and not yet classified: 1 of 132000, Human clinical research: 7 of 192000, Preclinical (animal, in vitro, computational): 10 of 192000, Reviews and meta-analyses: 2 of 192001, Human clinical research: 3 of 112001, Preclinical (animal, in vitro, computational): 6 of 112001, Reviews and meta-analyses: 1 of 112001, Other and not yet classified: 1 of 112002, Human clinical research: 5 of 132002, Preclinical (animal, in vitro, computational): 4 of 132002, Reviews and meta-analyses: 2 of 132002, Other and not yet classified: 2 of 132003, Human clinical research: 2 of 72003, Preclinical (animal, in vitro, computational): 5 of 72004, Human clinical research: 5 of 72004, Preclinical (animal, in vitro, computational): 2 of 72005, Human clinical research: 5 of 102005, Preclinical (animal, in vitro, computational): 4 of 102005, Other and not yet classified: 1 of 102006, Human clinical research: 6 of 132006, Preclinical (animal, in vitro, computational): 6 of 132006, Other and not yet classified: 1 of 132007, Human clinical research: 4 of 92007, Preclinical (animal, in vitro, computational): 4 of 92007, Reviews and meta-analyses: 1 of 92008, Human clinical research: 6 of 112008, Preclinical (animal, in vitro, computational): 4 of 112008, Other and not yet classified: 1 of 112009, Human clinical research: 5 of 92009, Preclinical (animal, in vitro, computational): 2 of 92009, Reviews and meta-analyses: 2 of 92010, Human clinical research: 9 of 192010, Preclinical (animal, in vitro, computational): 6 of 192010, Reviews and meta-analyses: 2 of 192010, Other and not yet classified: 2 of 192011, Human clinical research: 8 of 192011, Preclinical (animal, in vitro, computational): 7 of 192011, Reviews and meta-analyses: 2 of 192011, Other and not yet classified: 2 of 192012, Human clinical research: 5 of 182012, Preclinical (animal, in vitro, computational): 5 of 182012, Reviews and meta-analyses: 8 of 182013, Human clinical research: 5 of 182013, Preclinical (animal, in vitro, computational): 9 of 182013, Reviews and meta-analyses: 3 of 182013, Other and not yet classified: 1 of 182014, Human clinical research: 7 of 172014, Preclinical (animal, in vitro, computational): 8 of 172014, Reviews and meta-analyses: 2 of 172015, Human clinical research: 8 of 212015, Preclinical (animal, in vitro, computational): 9 of 212015, Reviews and meta-analyses: 3 of 212015, Other and not yet classified: 1 of 212016, Human clinical research: 9 of 232016, Preclinical (animal, in vitro, computational): 10 of 232016, Reviews and meta-analyses: 2 of 232016, Other and not yet classified: 2 of 232017, Human clinical research: 9 of 272017, Preclinical (animal, in vitro, computational): 8 of 272017, Reviews and meta-analyses: 7 of 272017, Other and not yet classified: 3 of 272018, Human clinical research: 5 of 162018, Preclinical (animal, in vitro, computational): 9 of 162018, Reviews and meta-analyses: 2 of 162019, Human clinical research: 9 of 302019, Preclinical (animal, in vitro, computational): 15 of 302019, Reviews and meta-analyses: 5 of 302019, Other and not yet classified: 1 of 302020, Human clinical research: 8 of 242020, Preclinical (animal, in vitro, computational): 9 of 242020, Reviews and meta-analyses: 7 of 242021, Human clinical research: 7 of 242021, Preclinical (animal, in vitro, computational): 10 of 242021, Reviews and meta-analyses: 7 of 242022, Human clinical research: 11 of 172022, Preclinical (animal, in vitro, computational): 3 of 172022, Reviews and meta-analyses: 3 of 172023, Human clinical research: 11 of 372023, Preclinical (animal, in vitro, computational): 16 of 372023, Reviews and meta-analyses: 9 of 372023, Other and not yet classified: 1 of 372024, Human clinical research: 8 of 272024, Preclinical (animal, in vitro, computational): 8 of 272024, Reviews and meta-analyses: 8 of 272024, Other and not yet classified: 3 of 272025, Human clinical research: 14 of 322025, Preclinical (animal, in vitro, computational): 11 of 322025, Reviews and meta-analyses: 5 of 322025, Other and not yet classified: 2 of 322026 (to date), Human clinical research: 9 of 182026 (to date), Preclinical (animal, in vitro, computational): 3 of 182026 (to date), Reviews and meta-analyses: 4 of 182026 (to date), Other and not yet classified: 2 of 18Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified01020304019731989199920092026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
197300011
197400011
197512025
197621003
197700011
198001012
198101012
198200011
198300011
198502002
198900011
199030003
199122004
199202002
199301012
199422015
199523005
19961120114
199743018
19985131019
1999291113
20007102019
2001361111
2002542213
200325007
200452007
2005540110
2006660113
200744109
2008640111
200952209
2010962219
2011872219
2012558018
2013593118
2014782017
2015893121
20169102223
2017987327
2018592016
20199155130
2020897024
20217107024
20221133017
202311169137
2024888327
202514115232
2026 (to date)934218

Study types

Animal study225
Other clinical trial82
Randomized controlled trial68
Review64
Observational human study37
Case report27
Meta-analysis21
Not yet classified21
In vitro study19
Editorial, letter or other17
Systematic review4
Computational study3
Guideline or consensus3

Research areas

From MeSH major topics. A paper can be in several areas.

Neurological and mental health550
Cardiovascular208
Cognitive health192
Tissue repair104
Immune system23
Metabolic health21
Musculoskeletal17
Longevity and aging16
Endocrinology12
Reproductive and sexual health7
Gastrointestinal6
Antimicrobial and infectious disease5

Registered clinical trials

8 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 18 · Unknown status: 10 · Not yet recruiting: 3 · Recruiting: 3 · Terminated: 3 · Active, not recruiting: 1 · Enrolling by invitation: 1 · Withdrawn: 1
Early phase 1: 1 · Phase not applicable: 9 · Phase 1: 1 · Phase 1 / Phase 2: 2 · Phase 2: 7 · Phase 2 / Phase 3: 2 · Phase 3: 5 · Phase 4: 13

TrialStatusPhaseStartedResults
Combined Acupuncture-Based Therapy for Rehabilitation After Ischemic StrokeNCT07846488 · 440 enrolledNot yet recruitingPhase not applicable2026-12—
Cerebrolysin After Reperfusion in Extended-window EndoVascular ThrombectomyNCT06339411 · 100 enrolledNot yet recruitingPhase 22026-09—
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point TrialNCT06899464 · 30 enrolledNot yet recruitingPhase 42025-10—
Cerebrolysin in Early Stroke Rehabilitation - Tertiary StudyNCT07043686 · 30 enrolledRecruitingPhase not applicable2025-06—
Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery OcclusionNCT06489925 · 20 enrolledUnknown statusEarly phase 12024-07—
Cerebrolysin in Critically Ill Patients With DeliriumNCT06677502 · 500 enrolledEnrolling by invitationPhase not applicable2024-01—
CERebrolysin In CADASILNCT05755997 · 30 enrolledActive, not recruitingPhase 22023-11—
A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)NCT06070753 · 30 enrolledUnknown statusPhase not applicable2023-10—
Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICUNCT06052787 · 150 enrolledCompletedPhase 32023-09—
Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's PalsyNCT05821075 · 90 enrolledRecruitingPhase 1, Phase 22023-08—
Efficacy and Safety of Cerebrolysin on Prolonged Disorders of ConsciousnessNCT04427241 · 12 enrolledRecruitingPhase 42023-06—
Cerebrolysin in Prevention of Postoperative Delirium in Cardiac SurgeryNCT05864677 · 100 enrolledUnknown statusPhase not applicable2023-01—
CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic StrokeNCT06078215 · 350 enrolledUnknown statusPhase 42023-01—
Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic StrokeNCT06273020 · 60 enrolledUnknown statusPhase 42022-11—
Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 VariantsNCT06208540 · 160 enrolledCompletedPhase 42021-08—
IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokENCT04124367 · 4 enrolledTerminatedPhase 22021-06—
Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled StudyNCT04913831 · 30 enrolledUnknown statusPhase 42021-06—
Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVTNCT05124353 · 100 enrolledUnknown statusPhase 2, Phase 32021-04—
Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.NCT04904341 · 50 enrolledUnknown statusPhase 32021-01—
Cerebrolycin for Treatment of Covid-related Anosmia and AgeusiaNCT04830943 · 250 enrolledCompletedPhase 32020-08—
Evaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain InjuryNCT05807503 · 56 enrolledCompletedPhase not applicable2020-02—
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative EffectivenessNCT03480698 · 1,851 enrolledCompletedPhase not applicable2018-04—
the Effect of Cerebrolysin on Physical and Mental Functions of Down SyndromeNCT04751136 · 64 enrolledCompletedPhase 22016-09—
Cerebrolysin and Neurodevelopment in Preterm InfantsNCT03506841 · 60 enrolledCompletedPhase 12016-06—
Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in StrokeNCT02768571 · 80 enrolledCompletedPhase 42016-03—
Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-ArmNCT02581371 · 30 enrolledUnknown statusPhase 42015-02—
Hair Repigmentation During Cerebrolysin TherapyNCT05288465 · 5 enrolledCompletedPhase not applicable2014-06—
Cerebrolysin REGistry Study in StrokeNCT02541227 · 1,823 enrolledTerminatedPhase not applicable2014-05—
Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral PalsyNCT02116348 · 100 enrolledUnknown statusPhase 22014-04—
Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid HemorrhageNCT01787123 · 50 enrolledCompletedPhase 2, Phase 32013-12—
The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and NeurorecoveryNCT01606111 · 46 enrolledTerminatedPhase 42013-09—
Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic EncephalopathyNCT01059461 · 40 enrolledCompletedPhase 22011-03—
Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.NCT01388738 · 30 enrolledCompletedPhase 32011-01—
Effects of Cerebrolysin on Motor Recovery in Patients With Subacute StrokeNCT01996761 · 71 enrolledCompletedPhase 42011-01—
Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic StrokeNCT02149875 · 84 enrolledCompletedPhase 1, Phase 22010-01Posted
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular DementiaNCT00947531 · 242 enrolledCompletedPhase 42006-10Posted
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic StrokeNCT00868283 · 1,071 enrolledCompletedPhase 42006-09—
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric StrokeNCT00840671 · 119 enrolledCompletedPhase 32005-10—
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's DiseaseNCT00911807 · 217 enrolledCompletedPhase 22004-10Posted
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)NCT01822951WithdrawnPhase 4——

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Cerebrolysin and Risk of Hemorrhagic Transformation: A Pooled Analysis of Recent Studies.

    Journal of clinical neurology (Seoul, Korea) · March 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 41775380 · DOI 10.3988/jcn.2025.0547 · Reviews and meta-analyses

  2. Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.

    Brain and behavior · March 1, 2026 · Meta-analysis · cited 2 times · open access

    PMID 41880098 · DOI 10.1002/brb3.71252 · Reviews and meta-analyses

  3. [The effect of Cerebrolysin on the development of skills in patients after acute cerebrovascular accidents].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · January 1, 2026 · Meta-analysis · cited 0 times

    PMID 41782528 · DOI 10.17116/jnevro202612602132 · Reviews and meta-analyses

  4. [Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation].

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · January 1, 2024 · Meta-analysis · cited 5 times · open access

    PMID 38512096 · DOI 10.17116/jnevro202412403255 · Reviews and meta-analyses

  5. The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.

    Journal of Alzheimer's disease : JAD · January 1, 2022 · Meta-analysis · cited 53 times

    PMID 34924395 · DOI 10.3233/jad-215423 · Reviews and meta-analyses

  6. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke.

    European journal of neurology · June 21, 2021 · Meta-analysis · cited 64 times · open access

    PMID 34152062 · DOI 10.1111/ene.14936 · Reviews and meta-analyses

  7. The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis.

    Cerebral circulation - cognition and behavior · April 16, 2021 · Meta-analysis · cited 12 times · open access

    PMID 36324709 · DOI 10.1016/j.cccb.2021.100012 · Reviews and meta-analyses

  8. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · February 23, 2021 · Meta-analysis · cited 22 times · open access

    PMID 33620612 · DOI 10.1007/s10072-020-04974-6 · Reviews and meta-analyses

  9. Cerebrolysin for acute ischaemic stroke.

    The Cochrane database of systematic reviews · July 14, 2020 · Meta-analysis · cited 18 times

    PMID 32662068 · DOI 10.1002/14651858.cd007026.pub6 · Reviews and meta-analyses

  10. Cerebrolysin for vascular dementia.

    The Cochrane database of systematic reviews · November 11, 2019 · Meta-analysis · cited 39 times

    PMID 31710397 · DOI 10.1002/14651858.cd008900.pub3 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke.

    Journal of neuroscience research · November 1, 2010 · Animal study · cited 194 times · open access

    PMID 20857512 · DOI 10.1002/jnr.22495 · Animal studies

  2. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

    Stroke · November 12, 2015 · Randomized controlled trial · cited 160 times · open access

    PMID 26564102 · DOI 10.1161/strokeaha.115.009416 · Human clinical research

  3. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke.

    Stroke · May 21, 2013 · Animal study · cited 147 times

    PMID 23696546 · DOI 10.1161/strokeaha.111.000831 · Animal studies

  4. Non-cholinergic strategies for treating and preventing Alzheimer's disease.

    CNS drugs · January 1, 2002 · Review · cited 142 times

    PMID 12421115 · DOI 10.2165/00023210-200216120-00003 · Reviews and meta-analyses

  5. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.

    Drugs of today (Barcelona, Spain : 1998) · April 1, 2012 · Review · cited 135 times

    PMID 22514792 · DOI 10.1358/dot.2012.48(suppl.a).1739716 · Reviews and meta-analyses

Latest publications

  1. Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.

    Journal of clinical medicine · November 9, 2026 · Not yet classified · cited 0 times · open access

    PMID 43030876 · DOI 10.3390/jcm15218734 · Not yet classified

  2. Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report.

    Case reports in neurological medicine · August 28, 2026 · Case report · cited 0 times · open access

    PMID 42666484 · DOI 10.1155/crnm/9962315 · Human clinical research

  3. Adjunctive Cerebrolysin therapy following mechanical thrombectomy for tandem right internal carotid artery and middle cerebral artery occlusion with residual post-procedural perfusion deficit: a case report.

    Journal of medicine and life · August 1, 2026 · Case report · cited 0 times · open access

    PMID 42891269 · DOI 10.25122/jml-2026-0102 · Human clinical research

  4. Research-Evidence-Practice Gaps in Post-stroke Neuro-recovery Pharmacological Therapies in Asia.

    Cerebrovascular diseases extra · July 29, 2026 · Observational human study · cited 0 times · open access

    PMID 42525569 · DOI 10.1159/000553635 · Human clinical research

  5. Improvement of aphasia deficits following traumatic intracranial hemorrhage: a case report.

    Journal of medicine and life · July 1, 2026 · Case report · cited 0 times · open access

    PMID 42751610 · DOI 10.25122/jml-2026-0072 · Human clinical research

  6. Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report.

    Journal of medicine and life · June 1, 2026 · Case report · cited 0 times · open access

    PMID 42602665 · DOI 10.25122/jml-2026-0081 · Human clinical research

  7. Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report.

    Journal of medicine and life · June 1, 2026 · Case report · cited 0 times · open access

    PMID 42602663 · DOI 10.25122/jml-2026-0057 · Human clinical research

  8. Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability.

    Cells · May 19, 2026 · In vitro study · cited 0 times · open access

    PMID 42193943 · DOI 10.3390/cells15100934 · In vitro studies

  9. Biochemical and Pharmacological Studies on Kynurenic Acid Metabolism in the <i>Helix pomatia</i>-Snail Model of Learning and Memory.

    Biomolecules · April 18, 2026 · Animal study · cited 0 times · open access

    PMID 42072724 · DOI 10.3390/biom16040603 · Animal studies

  10. Cerebrolysin and Risk of Hemorrhagic Transformation: A Pooled Analysis of Recent Studies.

    Journal of clinical neurology (Seoul, Korea) · March 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 41775380 · DOI 10.3988/jcn.2025.0547 · Reviews and meta-analyses

Browse all 591 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Cerebrolysin; FPE 1070

((TITLE_ABS:"Cerebrolysin" OR CHEM:"Cerebrolysin") OR (TITLE_ABS:"FPE 1070" OR CHEM:"FPE 1070" OR TITLE_ABS:"FPE1070" OR CHEM:"FPE1070")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Cerebrolysin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/cerebrolysin